Project description DEENESFRITPL An implant to treat chronic pain Following surgery, approximately 1% of patients will experience chronic pain. Current pharma treatments incur significant side effects including nausea and contribute to the opioid epidemic in the US. Chronic pain is the number one cause of long-term disability resulting in significant taxpayer costs of USD 635 billion and EUR 300 billiion to the United States and EU taxpayers respectively. The problem today is that Chronic Pain Patients are only considered for neurostimulation treatment once all other treatments fail at 5-7 years post diagnosis. The EU-funded CAPRI project will enable the universality of bioelectronics and treat the patient earlier in the pathway. The Capri device is performed under local anaesthetic and requires a single injection. Most importantly, the patient is discharged immediately after injection and self-manages at home. Show the project objective Hide the project objective Objective Persistent postoperative chronic pain (POCP) is defined as pain lasting for two or more months after surgery, when other causes of pain are excluded, such as cancer or chronic infection. The goal of the Capri-Stim project is to develop a product to replace current pain medication and nerve block injectable approaches for chronic pain.Capri-Stim is the only implant suitable for postoperative pain having an indwell duration of over 5 years with no side effects. Capri-Stim only requires one injection, is a low risk class 2 device, has an average selling price (ASP) of 50% less than current competitors. Capri-Stim enables the patient being discharged from the healthcare system after one visit and self managed from home. The technology is protected by 4 patent filingsPain medication is addictive and comes with significant side effects. Nerve block injectables need to be repeated at least every 3 months and have their own significant side effects. Other technologies have attempted to replace these approaches but have all failed as they all involve significant invasive surgical procedures, are susceptible to lead migration, are too large for intramuscular placement with inaccurate placement causing reduced efficacy.Developed in NUI-Galway, Capri-Stim is a new product and the only implant suitable for postoperative pain having an indwellduration of over 5 years with no side effects. Capri-Stim only requires one injection, is a low risk class 2 device, has an ASP of 50% less than current competitors. Overall the Capri-Stim product means that the patient can be discharged from the healthcare system after one visit and self managed from home. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicinesurgerysurgical proceduresmedical and health sciencesclinical medicineoncologymedical and health sciencesmedical biotechnologyimplants Keywords Chronic Neuropathic pain nervous system injectable neurostimulation implant Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-EIC-SMEInst-2018-2020-3 Funding Scheme SME-2 - SME instrument phase 2 Coordinator CAPRI MEDICAL LIMITED Net EU contribution € 2 396 489,00 Address 55 LANSDOWNE PARK D04W2K0 BALLSBRIDGE Ireland See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ireland Eastern and Midland Dublin Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 423 556,25